ELISA Sample Compatibility Guide: Can You Use Serum, Plasma, Tissue Homogenate, Cell Lysate, CSF, Saliva, or Urine?

When selecting an ELISA kit, one of the first practical questions researchers ask is:

Can this kit be used with my sample type?

In This Article

1. What Does Sample Compatibility Mean in ELISA?
2. Start with the Datasheet: Validated Sample Types Come First
3. Common ELISA Sample Types and Key Considerations
4. Can ELISA Kits Be Used with Non-Validated Sample Types?
5. How to Validate a Non-Validated Sample Type
6. Sample Preparation Factors That Affect ELISA Compatibility
7. Analyze ELISA Data Carefully After Matrix Testing
8. What Information Should You Provide When Asking Technical Support?
9. Frequently Asked Questions
10. Key Takeaway
11. References

For many projects, the sample may be serum, plasma, cell culture supernatant, tissue homogenate, cell lysate, cerebrospinal fluid (CSF), saliva, urine, or another biological fluid. In some cases, the kit datasheet clearly lists the intended sample type. In other cases, the sample type is not listed, and researchers need to determine whether the kit can still be used.

The short answer is: sample compatibility depends on the specific ELISA kit, the target analyte, the biological matrix, and whether the sample type has been validated.

If you are still selecting an assay, you can start by browsing Boster Bio ELISA Kits, then review the individual product datasheet for validated sample types.

This guide explains how to evaluate ELISA sample compatibility, what to check in the datasheet, and how to approach non-validated sample types.

1. What Does Sample Compatibility Mean in ELISA?

In ELISA, sample compatibility means that the assay can reliably detect and quantify the target analyte in a specific biological sample matrix.

Compatibility is not determined only by whether the target protein exists in the sample. It also depends on whether the sample matrix allows the assay to perform correctly.

A compatible sample type should generally allow:

• Specific antibody binding to the target analyte
• Acceptable signal-to-background ratio
• Reliable recovery of the analyte
• Linear response after sample dilution
• Quantification within the kit detection range
• Reproducible results across samples and replicates

Different sample types contain different levels of proteins, salts, enzymes, lipids, anticoagulants, detergents, endogenous biotin, or other interfering substances. These matrix components can affect antibody binding, enzyme activity, color development, background signal, and final concentration calculation. [1,2]

That is why a kit that works well with serum may not automatically perform the same way with saliva, urine, tissue homogenate, or cell lysate.

2. Start with the Datasheet: Validated Sample Types Come First

The first step is always to check the kit datasheet.

Most ELISA kit datasheets include a section listing validated, recommended, or tested sample types. These may include:

• Serum
• Plasma
• Cell culture supernatant
• Tissue homogenate
• Cell lysate
• CSF
• Saliva
• Urine
• Other biological fluids

If your intended sample type is listed, that is the best starting point. It means the manufacturer has evaluated the kit with that matrix or recommends that matrix based on available validation data.

However, researchers should still review the details carefully. Even when a sample type is listed, you should check:

• Species compatibility
• Sensitivity
• Recommended sample dilution
• Sample preparation instructions
• Storage and freeze-thaw guidance
• Plasma anticoagulant type, if plasma will be used
• Whether the expected analyte level is within the assay range

After checking the product datasheet, researchers may also review general ELISA workflow resources. Boster's ELISA Technical Resource Center provides supporting information for researchers planning ELISA experiments.

A listed sample type does not remove the need for good sample handling. Poor collection, storage, dilution, or preparation can still affect ELISA results. [3,4]

3. Common ELISA Sample Types and Key Considerations

Serum

Serum is one of the most common sample types for ELISA. It is often used to measure circulating proteins, cytokines, hormones, antibodies, biomarkers, and other soluble analytes.

Important considerations for serum samples include:

• Clotting time
• Hemolysis
• Lipemia
• Storage temperature
• Freeze-thaw cycles
• Expected analyte concentration
• Required dilution factor

Serum is generally a strong starting matrix for many ELISA kits, but not every analyte is stable or abundant in serum. Researchers should confirm that the kit detection range is appropriate for the expected concentration.

Plasma

Plasma is also commonly used in ELISA, but it differs from serum because it contains anticoagulants.

Common plasma types include:

• EDTA plasma
• Heparin plasma
• Citrate plasma

These anticoagulants may affect some assays differently. For example, certain anticoagulants may interfere with antibody binding, enzyme activity, or analyte stability. [5]

If the datasheet lists "plasma," check whether it specifies the type of plasma. If only one plasma type has been validated, do not assume that all plasma types are interchangeable.

In general, serum and plasma should not be treated as automatically equivalent without checking the kit documentation or performing matrix validation. [5]

Tissue Homogenate

Tissue homogenate is used when researchers want to measure proteins in solid tissues, such as brain, liver, lung, kidney, tumor tissue, or other organs.

Tissue homogenate can be more complex than serum or plasma because the result depends heavily on how the tissue is processed.

Key factors include:

• Tissue type
• Tissue weight
• Homogenization buffer
• Protease inhibitor use
• Centrifugation conditions
• Extraction efficiency
• Sample dilution
• Total protein normalization

If tissue homogenate is listed on the datasheet, follow the recommended preparation protocol as closely as possible.

If tissue homogenate is not listed, the kit may still be usable, but the matrix should be validated first. Spike recovery and dilution linearity testing are especially important for tissue extracts because tissue components can create matrix interference or high background. [1,2]

Additional Note for Tissue Homogenates: Endogenous Biotin

For ELISA kits that use a biotin-avidin, biotin-streptavidin, or ABC-based detection system, endogenous biotin in tissue homogenates may contribute to background signal or false-positive signal. This is especially relevant when testing tissue samples that have not been validated for the specific kit. [6]

Before running a full tissue sample set, researchers may consider a small pilot background check to evaluate whether endogenous biotin affects the assay.

A simple pilot check is to add the tissue homogenate to the wells, then add ABC reagent and TMB substrate without adding the biotinylated detection antibody. If no signal is observed, endogenous biotin is less likely to interfere under those assay conditions, and the tissue sample may be tested using the kit protocol.

If signal is observed, the background contribution from endogenous biotin should be considered before interpreting results. Additional optimization may be needed, such as adjusting sample dilution, improving sample preparation, or contacting technical support for kit-specific guidance.

Cell Lysate

Cell lysate is commonly used for intracellular proteins, signaling molecules, transcription factors, and other non-secreted targets.

The biggest compatibility concern with cell lysate is the lysis buffer.

Some buffer components may interfere with ELISA performance, including:

• Strong detergents
• High salt concentrations
• Reducing agents
• Chelators
• Organic solvents
• Certain protease inhibitor formulations

Before using cell lysates, check whether the kit protocol recommends a specific lysis buffer. If no buffer is specified, avoid aggressive lysis conditions unless compatibility has been confirmed. [2]

For comparative studies, researchers may also need to normalize samples by total protein concentration so that differences reflect analyte levels rather than unequal sample loading.

CSF

Cerebrospinal fluid, or CSF, is an important sample type in neuroscience, neuroinflammation, neurodegeneration, infection, and biomarker studies.

CSF has two major challenges:

1. Sample volume is often limited
2. Target analyte levels may be low

Before testing valuable CSF samples, researchers should confirm that the kit sensitivity is appropriate for the expected analyte concentration. If the analyte is near or below the lower detection limit, a high-sensitivity ELISA kit may be needed. [1]

Because CSF samples can be difficult to obtain, it is useful to perform a small pilot test before running the full sample set.

Saliva

Saliva is attractive because it is non-invasive and easy to collect. However, it can also be highly variable.

Potential issues include:

• Mucins
• Digestive enzymes
• Food or drink contamination
• Oral health status
• Collection time
• Viscosity
• Low or variable analyte concentration

Some ELISA kits are validated for saliva, but many are not. If saliva is not listed on the datasheet, matrix validation is strongly recommended before interpreting results.

Sample collection should also be standardized as much as possible. For example, researchers may need to control collection time, fasting status, stimulation method, and storage conditions. [7]

Urine

Urine can be useful for kidney injury markers, metabolic biomarkers, hormones, inflammation-related analytes, and other soluble targets. However, it is also a challenging matrix.

Urine composition can vary based on:

• Hydration status
• Time of collection
• Kidney function
• pH
• Salt concentration
• Protein concentration
• Storage conditions

Because urine is often low in protein, the target analyte may be present at low concentrations. Depending on the study design, researchers may need to normalize results to creatinine, total protein, or sample volume. [8]

If urine is not listed as a validated sample type, spike recovery and dilution linearity should be performed before using the kit for quantitative conclusions.

Cell Culture Supernatant

Cell culture supernatant is commonly used to measure secreted proteins, cytokines, chemokines, growth factors, and immune mediators.

Compatibility depends on several experimental variables:

• Cell type
• Cell density
• Culture duration
• Stimulation conditions
• Serum-containing or serum-free medium
• Phenol red or other media components
• Expected analyte secretion level

If the target analyte is secreted at low levels, the sample may need to be concentrated, or a more sensitive kit may be required.

Once the sample matrix is selected, researchers should follow the kit-specific manual and a validated workflow. Boster's ELISA Protocol resource can be used as a supporting reference for understanding general ELISA workflow design.

4. Can ELISA Kits Be Used with Non-Validated Sample Types?

Sometimes a researcher's sample type is not listed on the kit datasheet.

This does not always mean the kit cannot be used.

It usually means one of the following:

• The manufacturer has not tested that sample matrix
• The matrix has not been formally validated
• There is not enough data to officially recommend that sample type
• Additional optimization may be required

For example, an ELISA kit may be validated for serum and plasma, but a researcher may want to use tissue homogenate, saliva, urine, or CSF. In this case, the kit might still detect the analyte, but the sample matrix could affect recovery, background, linearity, or accuracy.

For non-validated sample types, results should be considered exploratory until the matrix is tested. [1]

Researchers should perform preliminary validation before using the data for publication, biomarker comparison, or important project decisions.

For projects that require deeper matrix testing, assay optimization, or antibody pair screening, Boster's ELISA Assay Development Services may be relevant, especially when catalog kits or existing reagents are not enough.

5. How to Validate a Non-Validated Sample Type

If your sample type is not listed on the datasheet, several basic tests can help determine whether the matrix is suitable.

1. Spike Recovery and Dilution Linearity Check

Spike recovery is commonly used to evaluate whether the sample matrix interferes with ELISA detection. In practice, it can be combined with a serial dilution check to evaluate both recovery and dilution linearity in the same workflow. [1]

A typical setup includes an unspiked sample group, a spiked sample group, and a control group prepared with sample diluent and the same amount of standard. After preparation, these groups can be tested undiluted and through serial dilutions, such as 1:2, 1:4, and 1:8. This allows researchers to evaluate whether the added standard can be recovered from the sample matrix and whether the measured signal changes proportionally after dilution.

Group	Purpose
Unspiked Group	Measures the endogenous analyte level in the test sample
Spiked Group	Measures recovery after adding a known amount of standard to the test sample
Control Group	Measures the same standard amount in sample diluent as a reference

Recovery can be calculated as:

Recovery Rate = (Spiked Group - Unspiked Group) / Control Group x 100%

The Boster spike-and-recovery workflow also includes serial dilution steps for the spiked, control, and unspiked groups, followed by recovery rate calculation.

A commonly used starting criterion is spike recovery within 80-120%, while dilution linearity should show consistent dilution-corrected concentrations across the tested range. Final acceptance criteria should be predefined for the specific kit, analyte, and intended use. [1]

Because standard concentration, reconstitution volume, dilution factor, and acceptable recovery range may vary by kit and target analyte, researchers should always follow the kit-specific manual and confirm the final setup with technical support when testing a non-validated sample matrix.

2. Background and Blank Controls

Some sample types may produce high background or nonspecific signal.

Useful controls may include:

• Assay blank
• Sample blank
• Negative control sample
• Buffer-only control
• Matrix-matched control, if available
• Tissue homogenate background check for endogenous biotin, when using a biotin-avidin or biotin-streptavidin detection system

These controls help determine whether the sample matrix contributes signal independent of the target analyte.

High background is more likely in complex matrices such as tissue homogenate, cell lysate, saliva, or poorly clarified samples.

If your lab does not have enough sample volume, time, or internal assay capacity to perform these checks, Boster's ELISA Testing Service may provide an alternative route.

6. Sample Preparation Factors That Affect ELISA Compatibility

Even when a sample type is generally compatible with a kit, sample preparation can strongly affect the result.

Collection Method

Sample collection should be consistent across experimental groups. Differences in collection tubes, anticoagulants, timing, or handling can introduce variability. [3,4]

Anticoagulants

For plasma samples, EDTA, heparin, and citrate may not behave the same way. Use the plasma type recommended by the kit whenever possible. [5]

Lysis or Homogenization Buffer

For cell lysate and tissue homogenate, buffer composition is critical. Strong detergents, high salt, or incompatible additives may reduce assay performance.

Endogenous Biotin

For tissue homogenates and other tissue-derived samples, endogenous biotin may be relevant when the kit uses a biotin-avidin, biotin-streptavidin, or ABC detection system.

This does not mean tissue samples cannot be used. It means that background signal from endogenous biotin should be considered, especially when the sample type has not been validated for that kit.

A small pilot background check may help determine whether the tissue matrix produces signal in the absence of the biotinylated detection antibody.

Protease Inhibitors

Protease inhibitors can help preserve analytes, especially in lysates and tissue homogenates. However, the inhibitor formulation should not interfere with the ELISA reaction.

Centrifugation and Clarification

Samples should usually be clarified before testing. Particulates, debris, lipids, or insoluble material can increase background or reduce reproducibility.

Storage and Freeze-Thaw Cycles

Repeated freeze-thaw cycles can degrade sensitive proteins. Aliquoting samples before storage can help reduce variability. [4]

Dilution

Proper dilution can reduce matrix interference and bring the analyte concentration into the assay range. However, excessive dilution may push low-abundance analytes below the detection limit.

Normalization

For tissue homogenate and cell lysate, results may need to be normalized to total protein concentration, tissue weight, cell number, or another relevant biological parameter.

7. Analyze ELISA Data Carefully After Matrix Testing

Sample compatibility does not end when the plate is read. After running spike recovery, dilution linearity, endogenous biotin background checks, or other controls, researchers still need to review the standard curve, replicate consistency, blank signal, and calculated sample concentrations.

For routine ELISA data processing, Boster's ELISA Data Analysis Tool can help researchers analyze raw OD values and review calculated results.

This can be useful when checking whether diluted samples fall within the reliable range of the assay and whether calculated concentrations remain consistent after dilution correction.

8. What Information Should You Provide When Asking Technical Support?

When contacting technical support about ELISA sample compatibility, include as much detail as possible.

Useful information includes:

• Kit catalog number
• Target analyte
• Species
• Intended sample type
• Sample preparation method
• Buffer composition
• Plasma anticoagulant type, if applicable
• Expected analyte concentration, if known
• Storage conditions
• Number of freeze-thaw cycles
• Whether the sample contains additives or preservatives
• Whether the sample is tissue-derived and may contain endogenous biotin
• Research goal, such as screening, comparison, quantification, or validation

A clear inquiry may look like this:

Providing these details helps technical support determine whether the sample type has been validated, whether any preparation changes are recommended, and whether additional matrix validation is needed.

If your project involves an unusual matrix, difficult biomarker, poor spike recovery, nonlinear dilution, high background, or possible endogenous biotin interference, Boster's ELISA Technical Resource Center and ELISA service pages can help you decide whether to use a catalog kit, adjust sample preparation, outsource testing, or consider custom assay development.

Frequently Asked Questions

Can I use an ELISA kit with a sample type not listed on the datasheet?

Possibly. A sample type that is not listed may still work, but it should be treated as non-validated. Researchers should perform preliminary validation, such as spike recovery, dilution linearity, background testing, and matrix-specific controls before relying on the results.

Are serum and plasma interchangeable in ELISA?

Not always. Plasma contains anticoagulants such as EDTA, heparin, or citrate, and these may affect some assays. Always check whether the datasheet specifies serum, plasma, or a particular plasma type.

Can ELISA kits be used with tissue homogenates?

Some ELISA kits are validated for tissue homogenate, while others are not. If tissue homogenate is not listed as a validated sample type, researchers should optimize the extraction method and perform matrix validation before interpreting the results. For kits using a biotin-avidin, biotin-streptavidin, or ABC-based detection system, researchers should also consider whether endogenous biotin in tissue homogenates may contribute to background signal.

Can cell lysates interfere with ELISA results?

Yes. Cell lysates may contain detergents, salts, protease inhibitors, reducing agents, or other buffer components that affect antibody binding or enzyme reaction. Use the recommended lysis buffer when available.

Can saliva or urine be used in ELISA?

Some kits support saliva or urine, but these matrices can be variable and may contain interfering substances. If saliva or urine is not listed on the datasheet, spike recovery and dilution linearity testing are recommended.

What tests help confirm sample compatibility?

Common tests include spike recovery, dilution linearity, and background control testing. In many workflows, spike recovery and dilution linearity can be evaluated together by testing unspiked, spiked, and control groups across serial dilutions.

What should I do if my analyte level is below the detection range?

If the analyte concentration is too low, researchers may need a more sensitive kit, a different sample preparation method, sample concentration, or a different sample type. Running a pilot test before using valuable samples is recommended.

After running these checks, researchers can use an ELISA Data Analysis Tool to review standard curve fitting, OD values, blank correction, and calculated concentrations.

Key Takeaway

ELISA sample compatibility depends on more than the name of the sample type. It depends on the specific kit, target analyte, biological matrix, sample preparation method, assay detection system, and validation data.

Before using an ELISA kit with serum, plasma, tissue homogenate, cell lysate, CSF, saliva, urine, or another sample type, start with the kit datasheet. If your sample type is listed, follow the recommended protocol. If your sample type is not listed, the kit may still be usable, but preliminary validation is recommended.

Spike recovery, dilution linearity, background control testing, and matrix-specific checks such as endogenous biotin evaluation can help determine whether a non-validated sample matrix is suitable for reliable ELISA quantification.

References

1. Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJC, et al. A Practical Guide to Immunoassay Method Validation. Front Neurol. 2015;6:179. doi:10.3389/fneur.2015.00179. PMID: 26347708.
2. Tate J, Ward G. Interferences in Immunoassay. Clin Biochem Rev. 2004;25(2):105-120. PMID: 18458713; PMCID: PMC1904417.
3. Tuck MK, Chan DW, Chia D, et al. Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group. J Proteome Res. 2009;8(1):113-117. doi:10.1021/pr800545q. PMID: 19072545.
4. Ellervik C, Vaught J. Preanalytical Variables Affecting the Integrity of Human Biospecimens in Biobanking. Clin Chem. 2015;61(7):914-934. doi:10.1373/clinchem.2014.228783. PMID: 25979952.
5. Biancotto A, Feng X, Langweiler M, Young NS, McCoy JP Jr. Effect of Anticoagulants on Multiplexed Measurement of Cytokine/Chemokines in Healthy Subjects. Cytokine. 2012;60(2):438-446. doi:10.1016/j.cyto.2012.05.019. PMID: 22705152.
6. Wang H, Pevsner J. Detection of Endogenous Biotin in Various Tissues: Novel Functions in the Hippocampus and Implications for Its Use in Avidin-Biotin Technology. Cell Tissue Res. 1999;296(3):511-516. doi:10.1007/s004410051311. PMID: 10370137.
7. Gröschl M. Current Status of Salivary Hormone Analysis. Clin Chem. 2008;54(11):1759-1769. doi:10.1373/clinchem.2008.108910.
8. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of Urinary Biomarkers to Creatinine During Changes in Glomerular Filtration Rate. Kidney Int. 2010;78(5):486-494. doi:10.1038/ki.2010.165. PMID: 20555318.